Abstracts Archive - Page 2058 of 2607 - ACR Meeting Abstracts

Abstract Number: 2651 • 2014 ACR/ARHP Annual Meeting
Predictors of Therapeutic Outcomes in Patients with Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Kazuhiko Arima², Masataka Umeda¹, Shoichi Fukui³, Ayako Nishino¹, Yoshikazu Nakashima¹, Takahisa Suzuki¹, Yoshiro Horai⁴, Tomohiro Koga⁴, Shin-ya Kawashiri², Naoki Iwamoto¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi⁵ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki, Japan, ⁴Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious organ disorder with a variety of symptoms. Despite advances in the understanding of the immunopathogenic and…
Abstract Number: 2650 • 2014 ACR/ARHP Annual Meeting
Cognitive Impairment in SLE and Non-Criterion Anti-Phospholipid Antibodies
Michael Luggen¹, Gaurav Gulati², Rohan Willis³ and Emilio B. Gonzalez³, ¹Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ³Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: The pathogenesis of cognitive impairment (CI) in patients with SLE is unknown. Anti-phospholipid antibodies (APL) have been implicated in some studies, but not in…
Abstract Number: 2649 • 2014 ACR/ARHP Annual Meeting
“Point of Care” Neurocognitive Testing for Neuropsychiatric Systemic Lupus Erythematosis (NPSLE)
Debbie Rybak¹, Nicole Jordan¹, Noa Schwartz¹, Tamar Rubinstein², Bryan Freilich³, Irene Blanco⁴ and Chaim Putterman⁵, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Psychiatry, Albert Einstein College of Medicine, Bronx, NY, ⁴Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose There is currently no standardized tool to assess for NPSLE, and comprehensive neuropsychological testing can be lengthy and expensive. The Automated Neuropsychological Assessment Metric…
Abstract Number: 2648 • 2014 ACR/ARHP Annual Meeting
Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Xiangyang Huang¹, Laurence S. Magder² and Michelle Petri³, ¹Sichuan University School of Medicine, Sichuan, China, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Depression affects as many as 30% of SLE patients. Most studies of risk factors for depression among SLE patients have been cross-sectional, and thus…
Abstract Number: 2647 • 2014 ACR/ARHP Annual Meeting
Predictors of Incident Seizure in Systemic Lupus Erythematosus
Xiangyang Huang¹, Laurence S. Magder² and Michelle Petri³, ¹Sichuan University School of Medicine, Sichuan, China, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We identified the rate and risk factors for first occurrences of seizure based on a large closely followed longitudinal cohort of patients with systemic…
Abstract Number: 2646 • 2014 ACR/ARHP Annual Meeting
Mood Disorders in Systemic Lupus Erythematousus (SLE): Results from an International, Inception Cohort Study
John G. Hanly for the Systemic Lupus International Collaborating Clinics¹, Li Su², Murray Urowitz³, Juanita Romero-Diaz⁴, Caroline Gordon⁵, Sang-Cheol Bae⁶, Sasha R Bernatsky⁷, Ann E. Clarke⁸, Daniel J. Wallace⁹, Joan T. Merrill¹⁰, David A. Isenberg¹¹, Anisur Rahman¹², Ellen M. Ginzler¹³, Paul Fortin¹⁴, Dafna D. Gladman¹⁵, Jorge Sanchez-Guerrero¹⁶, Michelle Petri¹⁷, Ian Bruce¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Cynthia Aranow²¹, Graciela S. Alarcon²², Barri J. Fessler²³, Kristján Steinsson²⁴, Ola Nived²⁵, Gunnar K. Sturfelt²⁵, Susan Manzi²⁶, Munther A. Khamashta²⁷, Ronald F. van Vollenhoven²⁸, Asad Zoma²⁹, Manuel Ramos-Casals³⁰, Guillermo Ruiz-Irastorza³¹, S. Sam Lim³², Thomas Stoll³³, Murat Inanc³⁴, Kenneth C. Kalunian³⁵, Diane L. Kamen³⁶, Peter Maddison³⁷, Christine A. Peschken³⁸, Søren Jacobsen³⁹, Anca Askanase⁴⁰, Jill P. Buyon⁴¹, Chris Theriault⁴², Kara Thompson⁴² and Vernon Farewell², ¹Division of Rheumatology, Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, Canada, ²MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ³Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion, Mexico city, Mexico, ⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁶Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, Canada, ⁸Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁹Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹²Centre for Rheumatology Research, University College London, London, United Kingdom, ¹³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹⁴Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, ¹⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁸Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁹Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²⁰Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, ²¹Feinstein Institute for Medical Research, Mahasset, NY, ²²Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²³Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁴Centre for Rheumatology Research, Landspital University Hospital, Reykjavik, Iceland, ²⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ²⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²⁷Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ²⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²⁹Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁰Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ³¹Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ³²Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³³Kantonsspital Geissbergstr, Schaffhausen, Switzerland, ³⁴Rheumatology, Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, ³⁵UCSD School of Medicine, La Jolla, CA, ³⁶Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ³⁷Ysbyty Gwynedd Bangor, North Wales, United Kingdom, ³⁸University of Manitoba, Canada, Winnipeg, MB, Canada, ³⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴⁰Columbia University Medical Center, New York, NY, ⁴¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴²Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Neuropsychiatric (NP) events in patients with SLE include mood disorders. We determined the frequency, characteristics, clinical and autoantibody associations of mood disorders in a…
Abstract Number: 2645 • 2014 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Pulse Cyclophosphamide for Neuropsychiatric Systemic Lupus Erythematosus: A Two-Centre Experience
Antonis Fanouriakis¹, Cristina Pamfil², Laura O. Damian³, Ioana Felea³, Emmanuel Mihali⁴, Ileana Filipescu², Theofanis Karageorgas⁵, Prodromos Sidiropoulos⁶, Simona Rednic², George Bertsias^6,7 and Dimitrios Boumpas^5,7,8, ¹Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ²Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, ³Rheumatology, Emergency Clinical County Hospital Cluj, Cluj-Napoca, Romania, ⁴Emergency Clinical County Hospital Cluj, Cluj-Napoca, Romania, ⁵Clinical Immunology and Rheumatology, "Attikon" University Hospital of Athens, Athens, Greece, ⁶Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁷Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece, ⁸Biomedical Research Foundation, Academy of Athens, Athens, Greece
Background/Purpose Cyclophosphamide (CYC) is often used in severe neuropsychiatric systemic lupus erythematosus. However, data on its use rely on small case series and a single…
Abstract Number: 2644 • 2014 ACR/ARHP Annual Meeting
Carotid Intima-Media Thickness and Plaque in Mexican Mestizos with Systemic Lupus Erythematosus: A Case-Control Study
Iris J. Colunga-Pedraza¹, Dionicio A. Galarza-Delgado¹, Alberto Cardenas-de La Garza¹, Ana L. Sanchez-Nuñez¹, Samantha L. Segarra-Linares¹, Rocío A. Carrillo-Palacios¹, David Vega-Morales¹, Fernando Góngora-Rivera² and Mario Alberto Garza-Elizondo¹, ¹Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ²Neurology., Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose Systemic lupus erythematosus (SLE) patients are at risk of premature cardiovascular disease (CVD). The specific reason of this situation is still debatable. Subclinical atherosclerosis…
Abstract Number: 2643 • 2014 ACR/ARHP Annual Meeting
Angiogenic and Antiangiogenic Factors in Patients with Systemic Lupus Erythematosus
Guilherme Ramires de Jesus¹, Camila Souto Oliveira², Flavia Cunha dos Santos³, Nilson Ramires de Jesus³, Luis Cristovao Porto⁴, Roger A. Levy⁵ and Evandro Mendes Klumb⁶, ¹Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Rheumatology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ³Obstetrics, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁴Immunology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose SLE mainly affects young women and pregnancy in these patients has significant morbidity and mortality. Clinical and laboratory findings in lupus nephritis are similar…
Abstract Number: 2642 • 2014 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study
Abha G. Singh¹, Cynthia S. Crowson², Mark Davis³, Hilal Maradit Kremers², Eric L. Matteson¹ and Vaidehi Chowdhary⁴, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Dermatology, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic inflammation is an independent risk factor for atherosclerosis; chronic inflammatory diseases such as systemic lupus erythematosus (SLE) are associated with increased risk of…
Abstract Number: 2641 • 2014 ACR/ARHP Annual Meeting
Cardiac Magnetic Resonance Imaging in Systemic Lupus Erythematosus
Alexa Meara¹, Namrata Dhillon², Kimberly Fisher³, Paul Jensen⁴ and Stacy P. Ardoin⁵, ¹Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Internal Medicine/Pediatrics, The Ohio State University, Nationwide Children's Hospital, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose Cardiac complications of SLE are common and include both acute and chronic manifestations: pericarditis, myocarditis, valvular disease, pulmonary hypertension, atherosclerosis, ischemic and non-ischemic cardiomyopathy. …
Abstract Number: 2640 • 2014 ACR/ARHP Annual Meeting
Prevalence and Predictors of ECG Cardiovascular Abnormalities in Lupus Patients
Zahi Touma¹, Paula Harvey², Dafna D. Gladman³, Dominique Ibanez¹, Arthy Sabapathy³ and Murray B. Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with lupus are at increased risk for cardiovascular disease. Previous studies on healthy adults showed that abnormalities detected on resting electrocardiography (ECG)…
Abstract Number: 2639 • 2014 ACR/ARHP Annual Meeting
Coronary-Artery Atherosclerosis in Males with Systemic Lupus Erythematosus
Juanita Romero-Díaz¹, Sergio Criales-Vera², Eric Kimura-Hayama², Roberto Ivan Acosta-Hernandez¹, Maricruz Dominguez-Quintana¹ and Jorge Sánchez-Guerrero³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose . Premature coronary-artery atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the…
Abstract Number: 2638 • 2014 ACR/ARHP Annual Meeting
The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies
Toshiyuki Watanabe, Kenji Oku, Olga Amengual, Eri Sugawara, Ryo Hisada, Kazumasa Ohmura, Tomoko Fukui, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Michihito Kono, Yuka Shimizu, Takashi Kurita, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Thrombosis is one of the most frequent manifestations in patients with systemic lupus erythematosus (SLE). Although antiphospholipid antibodies (aPL) are well recognized risk factors…
Abstract Number: 2620 • 2014 ACR/ARHP Annual Meeting
Mortality and Survival in Systemic Lupus Erythematosus Patients: Trends in a Spanish Cohort from 1985 to 2013
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Milagros Ricse¹, Gloria Albert¹, Eulalia Armengol¹, Helena Borrell¹, Olga Capdevila³, Francesca Mitjavila³, Toni Rozadilla¹, Xavier Juanola⁴ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To study the mortality, survival and causes of death in a Spanish cohort of patients with systemic lupus erythematosus (SLE) over a 28-year period…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].